Increased formation of 8-iso-prostaglandin F2α is associated with altered bone metabolism and lower bone mass in hypercholesterolaemic subjects

Journal of Internal Medicine

Volumn 261, Issue 6, 2007, Pages 587-596

  Mangiafico, R A ^a,c   Malaponte, G ^a   Pennisi, P ^a   Li Volti, G ^a,b   Trovato, G ^a   Mangiafico, M ^a   Bevelacqua, Y ^a   Mazza, F ^a   Fiore, C E ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Bone density; Hypercholesterolaemia; Lipids; Osteoporosis; Oxidative stress

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ALKALINE PHOSPHATASE BONE ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE TURNOVER; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; FEMUR NECK; HUMAN; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; LINEAR REGRESSION ANALYSIS; LIPID PEROXIDATION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; OXIDATIVE STRESS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; RELIABILITY; URINE LEVEL;

ADULT; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; CROSS-SECTIONAL STUDIES; DINOPROST; FEMALE; FEMUR NECK; HUMANS; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOCALCIN; OSTEOPROTEGERIN; OXIDATIVE STRESS; RANK LIGAND; STATISTICS, NONPARAMETRIC;

EID: 34249670768     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2007.01784.x     Document Type: Article

References (46)

1. Tankó LB, Bagger YZ, Christiansen C. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int 2003 73 : 15 20.
2. van der Klift M, Pols HA, Hak AE, Witteman JC, Hofman A, de Laet CE. Bone mineral density and the risk of peripheral arterial disease: the Rotterdam Study. Calcif Tissue Int 2002 70 : 443 9.
3. Barengolts EI, Berman M, Kukreja SC, Kouznetsova T, Lin C, Chomka EV. Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. Calcif Tissue Int 1998 62 : 209 13.
4. Uyama O, Yoshimoto Y, Yamamoto Y, Kawai A. Bone changes and carotid atherosclerosis in postmenopausal women. Stroke 1997 28 : 1730 2.
5. Pennisi P, Signorelli SS, Riccobene S et al. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int 2004 15 : 389 95.
6. Mangiafico RA, Russo E, Riccobene S et al. Increased prevalence of peripheral arterial disease in osteoporotic postmenopausal women. J Bone Miner Metab 2006 24 : 125 31.
7. Kannel WB, D'Agostino RB, Sullivan L, Wilson PW. Concept and usefulness of cardiovascular risk profiles. Am Heart J 2004 148 : 16 26.
8. Yamaguchi T, Sugimoto T, Yano S et al. Plasma lipids and osteoporosis in postmenopausal women. Endocr J 2002 49 : 211 7.
9. Broulik PD, Kapitola J. Interrelations between body weight, cigarette smoking and spine mineral density in osteoporotic Czech women. Endocr Regul 1993 27 : 57 60.
10. Tankó LB, Bagger YZ, Nielsen SB, Christiansen C. Does serum cholesterol contribute to vertebral bone loss in postmenopausal women Bone 2003 32 : 8 14.
11. Orozco P. Atherogenic lipid profile and elevated lipoprotein (a) are associated with lower bone mineral density in early postmenopausal overweight women. Eur J Epidemiol 2004 19 : 1105 12.
12. Poli A, Bruschi F, Cesana B, Rossi M, Paoletti R, Crosignani PG. Plasma low-density lipoprotein cholesterol and bone mass densitometry in postmenopausal women. Obstet Gynecol 2003 102 : 922 6.
13. Adami S, Braga V, Zamboni M et al. Relationship between lipids and bone mass in 2 cohorts of healthy women and men. Calcif Tissue Int 2004 74 : 136 42.
14. Solomon DH, Avorn J, Canning CF, Wang PS. Lipid levels and bone mineral density. Am J Med 2005 118 : 1414.
15. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000 283 : 3211 6.
16. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000 355 : 2218 9.
17. Schoofs MW, Sturkenboom MC, van der Klift M, Hofman A, Pols HA, Stricker BH. HMG-CoA reductase inhibitors and the risk of vertebral fracture. J Bone Miner Res 2004 19 : 1525 30.
18. LaCroix AZ, Cauley JA, Pettinger M et al. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med 2003 139 : 97 104.
19. van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA 2001 285 : 1850 5.
20. Reid IR, Hague W, Emberson J et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 2001 357 : 509 12.
21. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 : 23 33.
22. Parhami F, Tintut Y, Beamer WG, Gharavi N, Goodman W, Demer LL. Atherogenic high-fat diet reduces bone mineralization in mice. J Bone Miner Res 2001 16 : 182 8.
23. Parhami F, Morrow AD, Balucan J et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. Arterioscler Thromb Vasc Biol 1997 17 : 680 7.
24. Parhami F, Jackson SM, Tintut Y et al. Atherogenic diet and minimally oxidized low density lipoprotein inhibit osteogenic and promote adipogenic differentiation of marrow stromal cells. J Bone Miner Res 1999 14 : 2067 78.
25. Tintut Y, Parhami F, Tsingotjidou A, Tetradis S, Territo M, Demer LL. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANK L)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway. J Biol Chem 2002 277 : 14221 6.
26. Tintut S, Morony S, Demer LL. Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo. Arterioscler Thromb Vasc Biol 2004 24 : e6 10.
27. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ, II. A series of prostaglandin F2-like compounds are produced in vivo in humans by a noncyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 1990 87 : 9383 7.
28. Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000 28 : 505 13.
29. Davì G, Alessandrini P, Mezzetti A et al. In vivo formation of 8-epi-prostaglandin F2α is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997 17 : 3230 5.
30. Reilly MP, Praticò D, Delanty N et al. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation 1998 98 : 2822 8.
31. Basu S, Michaëlsson K, Olofsson H, Johansson S, Melhus H. Association between oxidative stress and bone mineral density. Biochem Biophys Res Commun 2001 288 : 275 9.
32. Paffenbarger RS, Jr., Wing AL, Hyde RT. Physical activity as an index of heart attack risk in college alumni. Am J Epidemiol 1978 108 : 161 75.
33. Ireland P, Jolley D, Giles G et al. Development of the Melbourne FFQ: a food frequency questionnaire for use in an Australian prospective study involving an ethnically diverse cohort. Asia Pac J Clin Nutr 1994 3 : 19 31.
34. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972 18 : 499 502.
35. Roberts LJ, Morrow JD. Isoprostanes as markers of lipid peroxidation in atherosclerosis. In : Serhan CN, Ward PA, eds. Molecular and Cellular Basis of Inflammation. Totowa, NJ : Humana Press, 1998 141 63.
36. Violi F, Cangemi R, Sabatino G, Pignatelli P. Vitamin E for the treatment of cardiovascular disease: is there a future Ann N Y Acad Sci 2004 1031 : 292 304.
37. Burger H, van Daele PL, Odding E et al. Association of radiographically evident osteoarthritis with higher bone mineral density and increased bone loss with age. The Rotterdam Study. Arthritis Rheum 1996 39 : 81 6.
38. Shouhed D, Kha HT, Richardson JA, Amantea CM, Hahn TJ, Parhami F. Osteogenic oxysterols inhibit the adverse effects of oxidative stress on osteogenic differentiation of marrow stromal cells. J Cell Biochem 2005 95 : 1276 83.
39. Mody N, Parhami F, Sarafian TA, Demer LL. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radical Biol Med 2001 31 : 509 16.
40. Xu H, Watkins BA, Seifert MF. Vitamin E stimulates trabecular bone formation and alters epiphyseal cartilage morphometry. Calcif Tissue Int 1995 57 : 293 300.
41. Morton DJ, Barrett-Connor EL, Schneider DL. Vitamin C supplement use and bone mineral density in postmenopausal women. J Bone Miner Res 2001 16 : 135 40.
42. Hall SL, Greendale GA. The relation of dietary Vitamin C intake to bone mineral density: results from the PEPI study. Calcif Tissue Int 1998 63 : 183 9.
43. Melhus H, Michaelsson K, Holmberg L, Wolk A, Ljunghall S. Smoking, antioxidant Vitamins, and the risk of hip fracture. J Bone Miner Res 1999 14 : 129 35.
44. Wolf RL, Cauley JA, Pettinger M et al. Lack of a relation between vitamin and mineral antioxidants and bone mineral density: results from the Women's Health Initiative. Am J Clin Nutr 2005 82 : 581 8.
45. Garrett IR, Boyce BF, Oreffo RO, Bonewald L, Poser J, Mundy GR. Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest 1990 85 : 632 9.
46. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000 15 : 2 12.